Malaria Vaccine Awareness, Access, and Equity: Challenges and Solutions

Malaria remains a critical public health issue, especially in sub-Saharan Africa, where it disproportionately affects vulnerable populations, including children under five. Despite promising breakthroughs, such as the World Health Organization (WHO)-approved RTS,S/AS01 malaria vaccine, challenges persist in vaccine awareness, access, and equitable distribution. This review examines current malaria vaccine implementation efforts, identifies systemic barriers, and highlights opportunities for enhancing uptake and equity. Key issues include inadequate community awareness, vaccine hesitancy, funding constraints, logistical limitations, and weak health infrastructure. Despite these barriers, innovative approaches such as scalable manufacturing, community engagement, and integrated delivery systems offer hope for achieving broader vaccine coverage. Addressing these challenges through multisectoral collaboration and targeted policy reform is essential for reducing malaria-related morbidity and mortality and progressing toward malaria elimination.

Malaria, Vaccine, Equity, Access, Vaccine Hesitancy, RTS, Sub-Saharan Africa

1. Adeloye D, Jacobs W, and Amuta AO,. (2017). Coverage and determinants of childhood immunization in Nigeria: A systematic review and meta-analysis. Vaccine. 2017;35(22):2871–2881. pmid:28438406. [Google Scholar] [Crossref]

2. Adeyemo AO, Aborode AT, Bello MA, et al. Malaria vaccine: the lasting solution to malaria burden in Africa. Ann Med Surg (Lond). 2022;79:104031. [Google Scholar] [Crossref]

3. Afolabi AA, Ilesanmi OS. Dealing with vaccine hesitancy in Africa: the prospective COVID-19 vaccine context. Pan Afr Med J. 2021;38:5–9. [Google Scholar] [Crossref]

4. Alonso PL. Malaria: a problem to be solved and a time to be bold. Nat Med. 2021;27:1506–9. [Google Scholar] [Crossref]

5. Angela E. Apeagyei, Nishali K. Patel, Ian Cogswell, Kevin O’Rourke, Golsum Tsakalos & Joseph Dieleman (2024). Examining geographical inequalities for malaria outcomes and spending on malaria in 40 malaria-endemic countries, 2010–2020. Malaria Journal volume 23, Article number: 206 [Google Scholar] [Crossref]

6. Aremu TO, Ajibola OA, Oluwole OE, Adeyinka KO, Dada SO, Okoro ON. Looking beyond the malaria vaccine approval to acceptance and adoption in Sub-Saharan Africa. Front Trop Dis. 2022;3:22. [Google Scholar] [Crossref]

7. Aremu TO, Singhal C, Ajibola OA, et al. Assessing public awareness of the malaria vaccine in Sub-Saharan Africa. Trop Med Infect Dis. 2022;7:215. [Google Scholar] [Crossref]

8. CDC—(2024). Malaria—Malaria Worldwide—Impact of Malaria. Published April 1 2024. AccessedJanuary23,2025. https://www.cdc.gov/malaria/malaria_worldwide/impact.html. [Google Scholar] [Crossref]

9. Chukwuocha UM, Okorie PC, Iwuoha GN, Ibe SN, Dozie IN, and Nwoke BE. (2018). Awareness, perceptions and intent to comply with the prospective malaria vaccine in parts of South Eastern Nigeria. Malar J. 2018;17(1):187. pmid:29720172 [Google Scholar] [Crossref]

10. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest. 2010;120:4168–78. [Google Scholar] [Crossref]

11. David B Olawade a, Ojima Z Wada b, Chiamaka Norah Ezeagu c, Nicholas Aderinto d,*, Malik A Balogun e, Fiyinfoluwa T Asaolu f, Aanuoluwapo Clement David-Olawade. (2024) Malaria vaccination in Africa: A mini-review of challenges and opportunities.PMCID: PMC11175883 PMID: 38875411Medicine (Baltimore).2024 Jun 14;103(24):e38565. doi: 10.1097/MD.0000000000038565 [Google Scholar] [Crossref]

12. Degarege A, Fennie K, Degarege D, Chennupati S, and Madhivanan P (2019). Improving socioeconomic status may reduce the burden of malaria in sub Saharan Africa: A systematic review and meta-analysis. PLOS ONE. 2019;14(1):e0211205. pmid:30677102 [Google Scholar] [Crossref]

13. Dimala CA, Kika BT, Kadia BM, and Blencowe H. (2018). Current challenges and proposed solutions to the effective implementation of the RTS, S/AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review. PloS One. 2018;13(12):e0209744. pmid:30596732 [Google Scholar] [Crossref]

14. Fact sheet about malaria. Accessed March 14, (2022). https://www.who.int/news-room/fact-sheets/detail/malaria. [Google Scholar] [Crossref]

15. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 pandemic on malaria control in Africa: a preliminary analysis. Trop Med Infect Dis. 2023;8:67. [Google Scholar] [Crossref]

16. Grant J, Gyan T, Agbokey F, Webster J, Greenwood B, Asante KP. Challenges and lessons learned during the planning and early implementation of the RTS,S/AS01E malaria vaccine in three regions of Ghana: a qualitative study. Malar J. 2022;21:147. [Google Scholar] [Crossref]

17. Immurana M, Boachie MK, Klu D, Dalaba MA, Manyeh AK, and Alhassan RK. (2022) Determinants of willingness to accept child vaccination against malaria in Ghana. Int J Health Plann Manage. n/a(n/a). pmid:34984733 [Google Scholar] [Crossref]

18. Ippolito MM, Moser KA, Kabuya JBB, Cunningham C, Juliano JJ. Antimalarial drug resistance and implications for the WHO global technical strategy. Curr Epidemiol Rep. 2021;8:46–62. [Google Scholar] [Crossref]

19. Kavanagh MM, Erondu NA, Tomori O, et al. Access to lifesaving medical resources for African countries:COVID-19 testing and response, ethics, and politics. Lancet.2020;395:1735–8 [Google Scholar] [Crossref]

20. MacDonald N, Mohsni E, Al-Mazrou Y, et al. Global vaccine action plan lessons I: recommendations for the next decade. Vaccine. 2020;38:5364–71. [Google Scholar] [Crossref]

21. MacDonald NE. (2015). Vaccine hesitancy: Definition, scope and determinants of Malaria Vaccine. 2015;33(34):4161–4164. pmid:25896383 [Google Scholar] [Crossref]

22. Makenga G, Bonoli S, Montomoli E, Carrier T, Auerbach J. Vaccine production in Africa: a feasible business model for capacity building and sustainable new vaccine introduction. Front Public Health. 2019;7:56. [Google Scholar] [Crossref]

23. Malar J. (2015) Social inequalities in malaria knowledge, prevention and prevalence among children under 5 years old and women aged 15–49 in Madagascar. PMCID: PMC4676822 PMID: 26651615 Dec 12;14:499. doi: 10.1186/s12936-015-1010-y [Google Scholar] [Crossref]

24. Mariwah S, Machistey Abane A, Asiedu Owusu S, et al. Formalising “informal” mHealth in Ghana: opportunities and challenges for Universal Health Coverage (UHC). Glob Public Health. 2022;17:768–81. [Google Scholar] [Crossref]

25. McCoy KD, Weldon CT, Malar J., and Ansumana R, (2021) . Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone. 20(1):1–12. pmid:33849572 [Google Scholar] [Crossref]

26. Merle CS. Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report. Malar J. 2023;22:242. [Google Scholar] [Crossref]

27. Mtenga S, Kimweri A., Malar J., and Romore I, (2016) Stakeholders’ opinions and questions regarding the anticipated malaria vaccine in Tanzania. 15(1):189. pmid:27048260 [Google Scholar] [Crossref]

28. Mumtaz H, Nadeem A, Bilal W, et al. Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: a review. Immun Inflamm Dis. 2023;11:e899. [Google Scholar] [Crossref]

29. Musa-Booth T, Enobun B, Agbomola A, and Shiff C. (2020). Knowledge, attitude and willingness to accept the RTS,S malaria vaccine among mothers in Abuja Nigeria. Published online 2020. [Google Scholar] [Crossref]

30. Nushaiba I (2021). Explained: Why It Took 54 Years For A Malaria Vaccine. https://www.indiaspend.com/health [Google Scholar] [Crossref]

31. Olufadewa I, Akinrinde D, Adesina M, Oladele R, Ayorinde T, Omo-Sowho U. The approval of the first malaria vaccine: the beginning of the end of the malaria epidemic. J Glob Health. 2022;12:03087. [Google Scholar] [Crossref]

32. Piot P, Larson HJ, O’Brien KL, et al. Immunization: vital progress, unfinished agenda. Nature. 2019;575:119–29. [Google Scholar] [Crossref]

33. Romore I, Ali AM, Semali I, Mshinda H, Tanner M, Abdulla S. and Malar J. (2015); Assessment of parental perception of malaria vaccine in Tanzania. 14(1):355. pmid:26383545 [Google Scholar] [Crossref]

34. Sallam M, Al-Khatib AO, Al-Mahzoum KS, Abdelaziz DH, Sallam M. Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions. Clin Pharmacol. 2025 Apr 1;17:29-47. doi: 10.2147/CPAA.S513282. PMID: 40191019; PMCID: PMC11971972. [Google Scholar] [Crossref]

35. Simas C, and Larson HJ. (2021) Overcoming vaccine hesitancy in low-income and middle-income regions. Nat Rev Dis Primer. 7(1):1–2. pmid:34112811 [Google Scholar] [Crossref]

36. Sinnis P, Fidock DA. The RTS, S vaccine- a chance to regain the upper hand against malaria? Cell. 2022;185:750–4. [Google Scholar] [Crossref]

37. Sulaiman SK, Musa MS, Tsiga-Ahmed FI, Dayyab FM, Sulaiman AK, and Bako AT (2022) A systematic review and meta-analysis of the prevalence of caregiver acceptance of malaria vaccine for under-five children in low-income and middle-income countries (LMICs). PLoS ONE 17(12): e0278224. https://doi.org/10.1371/journal.pone.0278224 [Google Scholar] [Crossref]

38. Tabiri D. (2020) Factors Associated with Malaria Vaccine Uptake in Sunyani Municipality. Thesis. University of Ghana; Accessed January 23, 2025. http://ugspace.ug.edu.gh/handle/123456789/36411. [Google Scholar] [Crossref]

39. Ughasoro MD, Bisi-Onyemaechi AI, and Okafor HU. (2018). Acceptance of malaria vaccine by a rural community in Nigeria. Niger J Med. 27(3):196–203. [Google Scholar] [Crossref]

40. UNICEF (2024). Nigeria Receives Malaria Vaccines Ahead of Roll Out. A joint press release by the National Primary Healthcare Development Agency, GAVI, UNICEF and WHO. 17 October 2024 [Google Scholar] [Crossref]

41. White SE, Harvey SA, and Meza G, (2018). Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study. 17(1):179. pmid:29703192 [Google Scholar] [Crossref]

42. WHO (2021).Recommends groundbreaking malaria vaccine for children at risk. Accessed January 23, 2025. https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk [Google Scholar] [Crossref]

43. WHO 2021, World malaria report (2021). https://www.who.int/publications-detail-redirect/9789240040496. [Google Scholar] [Crossref]

44. WHO. (2022). Over 1 million African children protected by first malaria vaccine. 2022. Available at: https://www.who.int/news/item/21-04-2022-over-1-million-african-children-protected-by-first-malaria-vaccine. [access date April 25, 2022]. [Google Scholar] [Crossref]

45. Wiysonge CS, Ndwandwe D, Ryan J, et al. Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Hum Vaccin Immunother. 2022;18:1–3. [Google Scholar] [Crossref]

46. Yeboah D, Owusu-Marfo J, Agyeman YN. Predictors of malaria vaccine uptake among children 6–24 months in the Kassena Nankana Municipality in the Upper East Region of Ghana. Malar J. 2022;21:1–10. [Google Scholar] [Crossref]